Andrew Obenshain, bluebird bio CEO

Blue­bird joins the lay­off flock to re­al­i­ty as gene ther­a­py biotech sheds staff to save it­self

Blue­bird bio is lay­ing off about 30% of its work­force to save it­self be­fore the FDA de­cides the fate of two of its gene ther­a­pies in Au­gust and Sep­tem­ber and plans to file for a third ap­proval in the first quar­ter of next year.

The dire sit­u­a­tion came in­to clear view ear­li­er this year when blue­bird said in a quar­ter­ly fil­ing its cash prob­lems “raise sub­stan­tial doubt re­gard­ing its abil­i­ty to con­tin­ue as a go­ing con­cern” in the com­ing year. The CFO re­signed the same day.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.